Rankings for Caribou Biosciences CRBU have been supplied by 4 analysts up to now three months, showcasing a mixture of bullish and bearish views.
The next desk summarizes their latest rankings, shedding mild on the altering sentiments inside the previous 30 days and evaluating them to the previous months.
| Bullish | Considerably Bullish | Detached | Considerably Bearish | Bearish | |
|---|---|---|---|---|---|
| Complete Rankings | 3 | 1 | 0 | 0 | 0 |
| Final 30D | 1 | 0 | 0 | 0 | 0 |
| 1M In the past | 1 | 0 | 0 | 0 | 0 |
| 2M In the past | 1 | 0 | 0 | 0 | 0 |
| 3M In the past | 0 | 1 | 0 | 0 | 0 |
Within the evaluation of 12-month value targets, analysts unveil insights for Caribou Biosciences, presenting a mean goal of $21.5, a excessive estimate of $24.00, and a low estimate of $19.00. A decline of 6.52% from the prior common value goal is obvious within the present common.
Exploring Analyst Rankings: An In-Depth Overview
A complete examination of how monetary consultants understand Caribou Biosciences is derived from latest analyst actions. The next is an in depth abstract of key analysts, their latest evaluations, and changes to rankings and value targets.
| Analyst | Analyst Agency | Motion Taken | Ranking | Present Value Goal | Prior Value Goal |
|---|---|---|---|---|---|
| Asthika Goonewardene | Truist Securities | Maintains | Purchase | $19.00 | – |
| Robert Burns | HC Wainwright & Co. | Maintains | Purchase | $24.00 | – |
| Robert Burns | HC Wainwright & Co. | Raises | Purchase | $24.00 | $23.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $19.00 | – |
Key Insights:
- Motion Taken: Responding to altering market dynamics and firm efficiency, analysts replace their suggestions. Whether or not they ‘Keep’, ‘Increase’, or ‘Decrease’ their stance, it signifies their response to latest developments associated to Caribou Biosciences. This gives perception into analysts’ views on the present state of the corporate.
- Ranking: Analysts unravel qualitative evaluations for shares, starting from ‘Outperform’ to ‘Underperform’. These rankings supply insights into expectations for the relative efficiency of Caribou Biosciences in comparison with the broader market.
- Value Targets: Analysts navigate by way of changes in value targets, offering estimates for Caribou Biosciences’s future worth. Evaluating present and prior targets gives insights into analysts’ evolving expectations.
Contemplating these analyst evaluations at the side of different monetary indicators can supply a complete understanding of Caribou Biosciences’s market place. Keep knowledgeable and make well-informed selections with our Rankings Desk.
Keep updated on Caribou Biosciences analyst rankings.
If you’re fascinated by following small-cap inventory information and efficiency you can begin by monitoring it right here.
All You Have to Know About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Commonly Interspaced Brief Palindromic Repeats (CRISPR) biopharmaceutical firm devoted to reworking the lives of sufferers with devastating ailments by making use of its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), towards the event of next-generation, genome-edited cell therapies. The corporate operates and handle enterprise as one reportable working section, which is the enterprise of creating a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Caribou Biosciences’s Financial Impression: An Evaluation
Market Capitalization Highlights: Above the business common, the corporate’s market capitalization signifies a big scale, indicating sturdy confidence and market prominence.
Unfavorable Income Development: Inspecting Caribou Biosciences’s financials over 3 months reveals challenges. As of 31 March, 2024, the corporate skilled a decline of roughly -30.64% in income progress, reflecting a lower in top-line earnings. As in comparison with rivals, the corporate encountered difficulties, with a progress price decrease than the typical amongst friends within the Well being Care sector.
Internet Margin: Caribou Biosciences’s internet margin excels past business benchmarks, reaching -1697.57%. This signifies environment friendly price administration and powerful monetary well being.
Return on Fairness (ROE): The corporate’s ROE is a standout performer, exceeding business averages. With a powerful ROE of -11.59%, the corporate showcases efficient utilization of fairness capital.
Return on Belongings (ROA): Caribou Biosciences’s ROA lags behind business averages, suggesting challenges in maximizing returns from its property. With an ROA of -9.83%, the corporate could face hurdles in reaching optimum monetary efficiency.
Debt Administration: With a below-average debt-to-equity ratio of 0.08, Caribou Biosciences adopts a prudent monetary technique, indicating a balanced strategy to debt administration.
How Are Analyst Rankings Decided?
Analyst rankings function important indicators of inventory efficiency, supplied by consultants in banking and monetary techniques. These specialists diligently analyze firm monetary statements, take part in convention calls, and have interaction with insiders to generate quarterly rankings for particular person shares.
Some analysts publish their predictions for metrics akin to progress estimates, earnings, and income to offer further steerage with their rankings. When utilizing analyst rankings, you will need to remember that inventory and sector analysts are additionally human and are solely providing their opinions to traders.
If you wish to preserve observe of which analysts are outperforming others, you may view up to date analyst rankings alongside withanalyst success scores in Benzinga Professional.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
